CorVel Corp. (NASDAQ:CRVL – Get Free Report) VP Jennifer Yoss sold 1,999 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $61.02, for a total value of $121,978.98. Following the completion of the transaction, the vice president directly owned 2,173 shares of the company’s stock, valued at $132,596.46. The trade was a 47.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
CorVel Stock Performance
NASDAQ:CRVL opened at $61.75 on Friday. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of 28.86 and a beta of 0.98. CorVel Corp. has a 52-week low of $44.83 and a 52-week high of $113.64. The stock has a fifty day moving average of $56.73 and a 200 day moving average of $61.26.
CorVel (NASDAQ:CRVL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 earnings per share (EPS) for the quarter. The company had revenue of $248.55 million during the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.
Institutional Investors Weigh In On CorVel
Analysts Set New Price Targets
Several research firms recently issued reports on CRVL. Wall Street Zen raised CorVel from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings lowered CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
View Our Latest Analysis on CorVel
CorVel Company Profile
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Recommended Stories
- Five stocks we like better than CorVel
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
